10X Genomics Announces Global Commercial Availability Of The Chromium System At The European Society Of Human Genetics (ESHG) Conference

PLEASANTON, Calif.--(BUSINESS WIRE)--10x Genomics, a company focused on improving and broadening the application of genomic information, today announced global commercial availability of their new Chromium™ System, a transformative upgrade for the predominant generation of short-read sequencers with the ability to unlock critical long-range genomic and cell-by-cell gene expression information.

“Shining a light in the ‘dark matter’ of the exome: using Linked-Reads and exome bait capture to map NGS short reads to genes and their paralogous segments”

“Global availability of our new Chromium System marks a significant milestone for 10x and the genomics community. The system enables multiple applications and gives customers access to crucial information that is not practically available through any other means. We expect that the Chromium System will be invaluable for a broad range of researchers and clinicians who want to capture the most value from their experiments and appreciate seamless integration of the technology into their current workflows,” said Serge Saxonov, co-founder and chief executive officer of 10x Genomics. “We are proud to deliver on our promise to expedite commercialization of this product and make it available to our current and future customers.”

The Chromium System enables multiple powerful applications and includes a suite of comprehensive workflow solutions including:

• The Chromium Single Cell 3’ Solution performs deep profiling of complex cell populations with high-throughput digital gene expression on a cell-by-cell basis. Tracing expression profiles to individual cells ensures biologically relevant signals are not masked by bulk average measurements.
• The Chromium Genome Solution provides comprehensive Linked-Read information on a genome-wide scale, combining the benefits of short-read data and long-range information. This includes variant calling, phasing and extensive characterization of genomic structure, enabling identification of critical variants in heritable disorders and discovery of key alterations in cancer.
• The Chromium Exome Solution provides Linked-Read information for phasing, structural variant detection and copy number determination, as well as giving researchers access to low-complexity and repetitive regions previously missed with short-read sequencing.
• The Supernova™ Assembler opens the door to high-quality, low-cost, everyday diploid de novo assemblies.

10x will be presenting scientific data for whole genome and exome applications of the Chromium System at the European Society of Human Genetics Conference taking place May 21-24 in Barcelona, Spain.

Customer data will be presented during ESHG at an educational workshop and after the conference during an informational webinar hosted by Nature Publishing Group. The presentation entitled, “Shining a light in the ‘dark matter’ of the exome: using Linked-Reads and exome bait capture to map NGS short reads to genes and their paralogous segments,” which will be presented by Hakon Hakonarson, Director of the Center for Applied Genomics at the Children’s Hospital of Philadelphia (CHOP) and also an associate professor of pediatrics at The University of Pennsylvania School of Medicine.

The webinar will be presented by Dr. Hakonarson on June 2, 2016 at 11am PDT / 2pm EDT. Interested parties can register for this free webinar via Nature Publishing Group.

About 10x Genomics

10x Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing sequencing technologies. This is achieved through a combination of new microfluidic science, chemistry and bioinformatics. By implementing GemCode™ Technology within the Chromium™ System, researchers can now, for the first time, find new structural variants, haplotypes, and other valuable genomic information with comprehensive workflows for Single Cell, Genome and Exome applications that incorporate their pre-existing sequencing technologies.